However, use of hormone receptor antagonistic medications, supported by the findings of these receptors in a subset of meningiomas, has been historically attempted with inconsistent results (66), at least in large part because of heterogeneity with how trials studies have been designed, results evaluated, and findings report (67). This evidence concerns the gene NR4A1 and meningioma.